Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: Implications for trastuzumab-based immunotherapy

British Journal of Cancer

Volumn 106, Issue 9, 2012, Pages 1543-1550

  Bellone, S ^a   Roque, D ^a   Cocco, E ^a   Gasparrini, S ^a   Bortolomai, I ^a   Buza, N ^a   Abu Khalaf, M ^a   Silasi, D A ^a   Ratner, E ^a   Azodi, M ^a   Schwartz, P E ^a   Rutherford, T J ^a   Pecorelli, S ^b   Santin, A D ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

CD46; CD55; CD59; Her2 neu; trastuzumab; Uterine serous cancer

Indexed keywords

CD59 ANTIGEN; DECAY ACCELERATING FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MEMBRANE COFACTOR PROTEIN; SMALL INTERFERING RNA; TRASTUZUMAB;

ADULT; AGED; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DOWN REGULATION; ENDOMETRIUM CELL; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UTERUS CARCINOMA;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD46; ANTIGENS, CD55; ANTIGENS, CD59; COMPLEMENT ACTIVATION; CYSTADENOCARCINOMA, SEROUS; CYTOTOXICITY, IMMUNOLOGIC; DOWN-REGULATION; FEMALE; FLOW CYTOMETRY; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, ERBB-2; RNA, SMALL INTERFERING; UTERINE CERVICAL NEOPLASMS;

EID: 84860235422     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.132     Document Type: Article

References (35)

1. Aigner A (2007) Applications of RNA interference: current state and prospects for siRNA-based strategies in vivo. Appl Microbiol Biotechnol 76: 9-21 (Pubitemid 47194678)
2. Baselga J, Carbonell X, Castañeda-Soto NJ, Clemens M, Green M, Harvey V, Morales S, Barton C, Ghahramani P (2005) Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 23(10): 2162-2171 (Pubitemid 46218708)
3. Bohkman JV (1983) Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15: 10-17
4. Caragine TA, Imai M, Frey AB, Tomlinson S (2002) Expression of rat complement control protein Crry on tumor cells inhibits rat natural killer cell-mediated cytotoxicity. Blood 100: 3304-3310 (Pubitemid 35217081)
5. Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6: 443-446 (Pubitemid 30208162)
6. Díaz-Montes TP, Ji H, Smith Sehdev AE, Zahurak ML, Kurman RJ, Armstrong DK, Bristow RE (2006) Clinical significance of Her-2/neu overexpression in uterine serous carcinoma. Gynecol Oncol 100: 139-144 (Pubitemid 41815063)
7. Donev RM, Cole DS, Sivasankar B, Hughes TR, Morgan BP (2006) p53 regulates cellular resistance to complement lysis through enhanced expression of CD59. Cancer Res 66: 2451-2458
8. El-Sahwi K, Bellone S, Cocco E, Cargnelutti M, Casagrande F, Bellone M, Abu-Khalaf M, Buza N, Tavassoli FA, Hui P, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD (2010) In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma. Br J Cancer 102: 134-143
9. El-Sahwi K, Schwartz PE, Santin AD (2012) Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer. Expert Review of Anticancer Therapy 12(1): 41-49
10. Fan Z, Masui H, Altas I, Mendelsohn J (1993) Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 53: 4322-4328 (Pubitemid 24146785)
11. Finberg RW, White W, Nicholson-Weller A (1992) Decay-accelerating factor expression on either effector or target cells inhibits cytotoxicity by human natural killer cells. Journal of Immunology 149(6): 2055-2060
12. Gelderman KA, Tomlinson S, Ross GD, Gorter A (2004) Complement function in mAb-mediated cancer immunotherapy. Trends Immunol 25: 158-164 (Pubitemid 38249490)
13. Gelderman KA, Lam S, Gorter A (2005) Inhibiting complement regulators in cancer immunotherapy with bispecific mAbs. Expert OpinBiol Ther 5: 1593-1601 (Pubitemid 41771850)
14. Gorter A, Meri S (1999) Immune evasion of tumor cells using membrane bound complement proteins. Immunol Today 20: 576-582
15. Grushko TA, Filiaci VL, Mundt AJ, Ridderstra°le K, Olopade OI, Fleming GF. Gynecologic Oncology Group (2008) An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 108: 3-9 (Pubitemid 350299437)
16. Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R (1982) Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 6: 93-108 (Pubitemid 12108965)
17. Iida Y, Takeda J, Miyata T, Inoue N, Nishimura J, Kitani T, Maeda K, Kinoshita T (1994) Characterization of genomic PIG-A gene: a gene for glycosylphosphatidylinositol-anchor biosynthesis and paroxysmal nocturnal hemoglobinuria. Blood 83(11): 3126-3131 (Pubitemid 24158455)
18. Kohler MF, Berchuck A, Davidoff AM, Humphrey PA, Dodge RK, Iglehart JD, Soper JT, Clarke-Pearson DL, Bast Jr RC, Marks JR (1992) Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res 52(6): 1622-1627
19. Kusama T, Miyagawa S, Moritan T, Kubo T, Yamada M, Sata H, Fukuta D, Matsunami K, Shirakura R (2003) Downregulation of NK cell-mediated swine endothelial cell lysis by DAF (CD55). Transplant Proc 35: 529-530 (Pubitemid 36194724)
20. Li W, Geis N, Kirschfink M (2009) Specific targeting of anti-CD59 siRNA by Herceptin-conjugated liposomes improves complement-mediated cytotoxicity of breast carcinoma cell. Mol Immunol 46: 2830-2831
21. Li W, Szoka Jr FC (2007) Liquid based-nanoparticles for nucleic acid delivery. Pharma Res 24: 438-449 (Pubitemid 46295166)
22. Macor P, Tripodo C, Zorzet S, Piovan E, Bossi F, Marzari R, Amadori A, Tedesco F (2007) In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res 67(21): 10556-10563 (Pubitemid 350070832)
23. Morrison C, Zanagnolo V, Ramirez N, Cohn DE, Kelbick N, Copeland L, Maxwell GL, Fowler JM (2006) HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J Clin Oncol 24: 2376-2385 (Pubitemid 46630670)
24. Mutch DG (2012) The more things change the more stay the same. Gynecol Oncol 124: 3-4
25. Rose PG (1996) Endometrial carcinoma. N Engl J Med 335: 640-649 (Pubitemid 26277956)
26. Santin AD, Bellone S, Gokden M, Palmieri M, Dunn D, Agha J, Roman JJ, Hutchins L, Pecorelli S, O'Brien T, Cannon MJ, Parham GP (2002) Overexpression of HER-2/neu in uterine serous papillary cancer. Clin Cancer Res 8: 1271-1279 (Pubitemid 34517668)
27. Santin AD, Bellone S, Roman JJ, McKenney JK, Pecorelli S (2008) Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. Int J Gynaecol Obstet 102: 128-131
28. Santin AD, Bellone S, Siegel ER, Palmieri M, Thomas M, Cannon MJ, Kay HH, Roman JJ, Burnett A, Pecorelli S (2005a) Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer. Am J Obstet Gynecol 192: 813-818 (Pubitemid 40311274)
29. Santin AD, Bellone S, Van Stedum S, Bushen W, De Las Casas LE, Korourian S, Tian E, Roman JJ, Burnett A, Pecorelli S (2005b) Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization. Gynecol Oncol 98: 24-30 (Pubitemid 40826414)
30. Santin AD, Bellone S, Van Stedum S, Bushen W, Palmieri M, Siegel ER, De Las Casas LE, Roman JJ, Burnett A, Pecorelli S (2005c) Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. Cancer 104: 1391-1397 (Pubitemid 41356154)
31. Schwartz PE. The management of serous papillary uterine cancer (2006) Curr Opin Oncol 18: 494-499
32. Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236
33. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792 (Pubitemid 32222155)
34. Villella JA, Cohen S, Smith DH, Hibshoosh H, Hershman D (2006) HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications. Int J Gynecol Cancer 16: 1897-1902 (Pubitemid 44470053)
35. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137 (Pubitemid 33674041)